Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance [Yahoo! Finance]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Yahoo! Finance
GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense of $185.0 Million, at the Low End of the Expected Guidance Range of $185 Million to $190 Million Evolysse™ Received U.S. Food and Drug Administration (FDA) Approval in February for Dynamic Facial Lines and Folds and is the First Hyaluronic Acid (HA) Filler to Recognize Weight Loss in the Patient Label as a Factor in Wrinkle Formation, Highlighting the Opportunity to Address GLP-1 Patients 2025 Net Revenue Guidance of $345 Million to $355 Million, Which Represents 30% to 33% Growth from 2024 Results; Evolysse™ and Estyme®
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.MarketBeat
- Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability [Yahoo! Finance]Yahoo! Finance
- The Dr. Randi Show Podcast, Sponsored by NewBeauty, Ranks in the Top 10% Globally for Conversations in Aesthetics, Beauty, Wellness & Medicine [Yahoo! Finance]Yahoo! Finance
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Moxie Announces Aesthetic Business Advisory Board and Scale Society Community to Shape the Next Era of Aesthetic MedicinePR Web
EOLS
Earnings
- 11/5/25 - Beat
EOLS
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- EOLS's page on the SEC website